Cutler Group’s Cyclerion Therapeutics CYCN Stock Holding History

Cutler Group’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10	Closed	–	–	5466
2021 Q3	$0	Hold	10	–	–	﹤0.01%	5802
2021 Q2	$0	Buy	+10	New	+$626	﹤0.01%	5779

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cutler Group's CYCN Position: Q4 2021 in Review

Cutler Group sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 10 shares.

Cutler Group first reported a position in CYCN in Q2 2021 and held it in 2 quarters. The position peaked at $0 in Q3 2021. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

Cutler Group reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 10 Cyclerion Therapeutics shares in Q4 2021.
Cutler Group first reported a position in Cyclerion Therapeutics in Q2 2021 and held it in 2 quarters.
Cutler Group's Cyclerion Therapeutics position peaked at $0 in Q3 2021.
56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.